TRAF2 and nasopharyngeal carcinoma: Although no mutations in other NF-κB pathway components (e.g., TRAF2, TRAF3, NLRC5) were detected, mutated NF-κB proteins remain promising druggable targets, particularly for metastatic NPC [19,28,29,31,33,43].